Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zocaglusagene nuzaparvovec - Astellas

Next Previous
Drug Profile

Zocaglusagene nuzaparvovec - Astellas

Alternative Names: AT 982; AT-002 - Astellas Gene Therapies; AT845

Latest Information Update: 03 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Audentes Therapeutics
  • Developer Astellas Gene Therapies
  • Class Gene therapies
  • Mechanism of Action Alpha-glucosidase replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glycogen storage disease type II

Most Recent Events

  • 22 Feb 2023 Adverse events and efficacy data from a phase-I/II FORTIS trial in Glycogen storage disease type II released by Astellas Pharma
  • 06 Feb 2023 Astellas Pharma plans to reinitiate the FORTIS phase I/II clinical trial of AT 845 in adults with late-onset Pompe disease (LOPD) in second quarter of 2023
  • 19 Jan 2023 US FDA lifts clinical hold from the FORTIS phase I/II trial in Glycogen storage disease type II

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top